Results 211 to 220 of about 17,055 (292)

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study. [PDF]

open access: yesNat Commun
Nadeem O   +32 more
europepmc   +1 more source

An Eosinophilic Esophagitis Endoscopic Reference Score Threshold of 2 or Less Is Robust for Assessing Endoscopic Response to Treatment of Eosinophilic Esophagitis. [PDF]

open access: yesAm J Gastroenterol
Reed CC   +17 more
europepmc   +1 more source

Association of Deep Learning Imaging Algorithm Measures of Microbial Keratitis With Vision Outcomes. [PDF]

open access: yesCornea
Vogt EL   +19 more
europepmc   +1 more source

Differences in Clinical Presentation and Treatment Response of Patients With Eosinophilic Esophagitis Complicated by Esophageal Food Impaction. [PDF]

open access: yesGastro Hep Adv
Redd WD   +16 more
europepmc   +1 more source

Assessing for Disparities in Diagnostic Delay Among Patients With Eosinophilic Esophagitis. [PDF]

open access: yesClin Gastroenterol Hepatol
Redd WD   +5 more
europepmc   +1 more source

Correction: SARS-CoV-2 seroepidemiology in Cape Town, South Africa, and implications for future outbreaks in low-income communities. [PDF]

open access: yesPLOS Glob Public Health
Hussey H   +23 more
europepmc   +1 more source

Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure. [PDF]

open access: yesHemasphere
Merrill MH   +24 more
europepmc   +1 more source

Pre-Exposure Prophylaxis Adherence and HIV Self-Testing App Among Women in the South Bronx: 12-Month Usability, Acceptability, and Feasibility Study. [PDF]

open access: yesJMIR Form Res
Wright CG   +13 more
europepmc   +1 more source

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade. [PDF]

open access: yesBlood Neoplasia
Merryman RW   +23 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy